FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2452-2459 December 18, 2003 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Relationships between academic institutions and industry in the life sciences continue to fascinate, perplex, trouble, and embarrass academic investigators, university administrators, industrial companies, and government policymakers. No matter how many solemn conferences are convened to address the issues raised by academic–industrial relationships, the controversy these relationships cause seems to persist and even grow. This situation reflects both the periodic eruption of scandal, such as that following the death in 1999 of a young volunteer during an industry-related clinical trial of gene therapy at the University of Pennsylvania,¹ and the increasing complexity of the relationship. Recently, academic and government officials recognized . . . [Full Text of this Article]

The History of Academic–Industrial Relationships

Ups and Downs

Public Promotion of Academic–Industrial Relationships

The Consequences of Academic–Industrial Relationships

Managing the Relationships

The Future

Source Information

From the Institute for Health Policy, Massachusetts General Hospital–Partners Health Care System, Boston.

This article has been cited by other articles:

• Azoulay, P., Michigan, R., Sampat, B. N. (2007). The Anatomy of Medical School Patenting. NEJM 357: 2049-2056 [Abstract] [Full Text]  
• Friedman, J. Y, Sugarman, J., Dhillon, J. K, DePuy, V., Pierre, C. K, Dinan, M. A, Allsbrook, J. S, Schulman, K. A, Weinfurt, K. P (2007). Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participants. Clin Trials 4: 272-278 [Abstract]  
• Okike, K., Kocher, M. S. (2007). The Legal and Ethical Issues Surrounding Financial Conflict of Interest in Orthopaedic Research. JBJS 89: 910-913 [Full Text]  
• Okike, K., Kocher, M. S., Mehlman, C. T., Bhandari, M. (2007). Conflict of Interest in Orthopaedic Research. An Association Between Findings and Funding in Scientific Presentations. JBJS 89: 608-613 [Abstract] [Full Text]  
• Brockway, L. M., Furcht, L. T. (2006). Conflicts of interest in biomedical research-- the FASEB guidelines. FASEB J. 20: 2435-2438 [Abstract] [Full Text]  
• Goven, J. (2006). Processes of Inclusion, Cultures of Calculation, Structures of Power: Scientific Citizenship and the Royal Commission on Genetic Modification. Science Technology Human Values 31: 565-598 [Abstract]  
• Topol, E. J., Blumenthal, D. (2005). Physicians and the Investment Industry. JAMA 293: 2654-2657 [Full Text]  
• Hill, D. E., Brasch, M. A., del Campo, A. A., Doucette-Stamm, L., Garrels, J. I., Glaven, J., Hartley, J. L., Hudson, J. R. Jr., Moore, T., Vidal, M. (2004). Academia-Industry Collaboration: An Integral Element for Building "Omic" Resources. Genome Res 14: 2010-2014 [Full Text]  
• Rabe, K.F., Sterk, P.J. (2004). From the Editors. Eur Respir J 23: 791-791 [Full Text]  
• Steinbrook, R. (2004). Financial Conflicts of Interest and the NIH. NEJM 350: 327-330 [Full Text]